Figure 13: Photograph of nurses administering insulin shock therapy in Lngbro Hospital, Stockholm, in 1930, credit: Wikipedia
The benefits of triple agonism extended also to MASLD in a subgroup of 98 people, fat content normalised in approximately 90% of people receiving the highest retatrutide doses [82]
GLP-1 medications remain expensive, with costs often exceeding $1,000 per month without insurance coverage
The last category of innovations, which is targeted at reducing the negative side effects, is more experimental
GLP-1 RAs commonly cause gastrointestinal symptoms, and those symptoms increase at higher doses
The trend has been gaining traction since last October, when Dr Andrew Huberman, a neuroscientist at Stanford University school of medicine and podcaster, posted an interview on X with the performance medicine expert Dr Craig Koniver, who hailed it as a gamechanger